이번주 수요 시사영어 강의 기사 : 기대하시라, 코로나 알약 백신, 스프레이 백신

※ "꿈"이 있다고 해서 공무원 시험이나 인터뷰에서 합격할 수 있는 건 아닙니다.더욱 중요한 요인은 '영리함'입니다. '영리함'은 타고나기도 하지만, 훈련을 통해 길러질 수도 있습니다.그 훈련이 바로 "요목조목" 따져보는 것입니다. (바둑, 체스의 수읽기처럼) 단어장, 수험서 같은 "교재"의 정답을 달달 암기하는 방식은결코 '영리함'을 길러주지 못합니다. 수요 시사영어 시간에복잡한 문장 구조와 창의적인 표현을 가지고요목조목 따져보는 훈련을 하시면영어쪽으로 많이 '영리'해집니다. 그렇게 길러진 '영리함'은인생의 다른 분야에도 큰 도움이 될 것입니다. -------------------------------------------------------------------- Get ready for the next wave of COVID vaccines There are more than 10 effective COVID-19 vaccines in use around the world, so it‘s easy to forget those still in development. That’s a mistake. These candidates may be taking longer to arrive, but they‘re essential to the pandemic fight. Most of the world is still unvaccinated, keeping the virus threat alive, and wherever it is able to spread unchecked there’s a risk of variants cropping up that can evade the protection offered by the current crop of shots. Governments need everything they can get and these shots offer the promise of billions of doses of reinforcements.Of the dozens of vaccine programs in human testing, there are some standouts. Here are four of them, including their status, advantages and challenges.  NovavaxStatus: US-based Novavax already has positive data in hand from extensive studies of its vaccine in South Africa and the UK that show protection against the original virus strain and variants. A large US trial will reveal more data soon. While manufacturing and regulatory holdups pushed back the company‘s potential regulatory filing from this quarter into the third, the rollout is finally in sight.Advantages: There’s solid evidence of efficacy for the shot, which uses tiny proteins to produce an immune response and a booster called an adjuvant to enhance it, and the company is laying groundwork to make many doses.Challenges: Novavax’s manufacturing efforts have been held up by shortages of things like giant bags used to grow cells and it remains vulnerable to further similar disruptions.  CureVacStatus: The German biotechnology firm started a large late-stage placebo-controlled study of its vaccine -- which uses the same type of messenger RNA technology that powers the Pfizer-BioNTech and Moderna shots -- in December. Recruitment is complete and the company hopes to release data and apply for authorization before the end of June.Advantages: The success of the Pfizer-BioNTech and Moderna vaccines have raised expectations for shots using mRNA technology, and Curevac‘s version may be a further improvement. The company modifies the RNA molecule differently, which lets it use a smaller dose. That will help it make more vaccines quickly, especially with the help of partnerships it formed with GlaxoSmithKline, Bayer, and Novartis.Challenges: CureVac must prove that its lower dose provides enough protection. On the supply-chain front, mRNA-focused companies have faced shortages of specialized equipment and ingredients because the technology they’re using is newer.   중략............    ------------------------------------------------------------------------------------※ 제 해설을 듣고 주요 문장을 암기하세요.그러면, 독해력이 발달하고, 좋은 정보를 더 빨리, 더 많이, 더 정확히 얻을 수 있는 능력이 생깁니다.